Glenmark lands first new chemical entity in Europe with acne cream
Winlevi, a first-in-class topical acne drug, is now on sale in the Nordics, Central Europe, and Spain. The filing includes zero financial projections.
— 4 earlier stories on Glenmark Pharmaceuticals Ltd. →What's new
- Glenmark launched Winlevi (clascoterone) cream for acne in the Nordics, Central Europe, and Spain.
- It is the company's first new chemical entity (not a generic) launch in Europe.
- Marketing authorization was granted to Cassiopea, a Cosmo subsidiary. Glenmark plans further European partnerships.
Why this matters
The launch proves Glenmark can execute a differentiated, not generic, product rollout in a regulated market. For a company that recently cut its FY27 margin guidance, that's a qualitative positive. But without revenue or market-size data, the commercial impact is impossible to gauge.
What we're watching
- Whether Glenmark or partners disclose revenue, pricing, or market-size data for Winlevi.
- The terms and timing of the planned expansion into additional European markets.
- Any impact on the revised 21-22% FY27 EBITDA margin guidance.
The full read
Glenmark has taken its first new chemical entity to market in Europe. Winlevi, a first-in-class acne cream, is now on sale across the Nordics, Central Europe, and Spain. It is the first topical androgen-receptor inhibitor approved anywhere. The European Commission granted marketing authorization to Cassiopea, a Cosmo subsidiary, in October 2025. For a company with a ₹60,563 cr market cap that recently trimmed margin guidance to 21-22%, this is a qualitative win. It proves the firm can execute a differentiated launch, not just a generic rollout. The problem is simple: the filing includes zero financial projections. No revenue. No market size. No margin impact. The launch is strategically positive but financially opaque. The next test is whether Glenmark discloses the commercial terms in its next update.
Questions answered
- What is Winlevi and why is its launch notable for Glenmark?
- Winlevi (clascoterone) is the first topical androgen-receptor inhibitor for acne. Its launch marks the first time Glenmark has commercialized a new chemical entity, as opposed to a generic drug, in Europe.
- Which markets are live, and what's planned next?
- The cream is now available in the Nordics, Central and Eastern Europe, and Spain. Glenmark has stated it expects to expand availability through additional partnerships across Europe.
- Does the filing provide any financial metrics for the product?
- No. The press release contains no revenue projections, market-size estimates, or details on the expected financial impact of the launch.
- How does this relate to Glenmark's recent margin guidance cut?
- Glenmark recently trimmed its FY27 EBITDA margin guidance to 21-22% from 23%. The Winlevi launch is a strategic expansion into a new therapeutic area, but the absence of financial data means its effect on that margin outlook is unknown.
Glenmark Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on GLENMARK →- 11 Jun 2026 · 10:22 AM IST Glenmark lands first new chemical entity in Europe with acne cream
- 4d ago Glenmark starts Phase 3 trial for ovarian cancer ADC in India
- 6d ago Glenmark gets six FDA observations at Goa plant; supply unaffected
- 31d ago Glenmark's transcript adds detail to its margin cut and Envafolimab delay
- 35d ago Glenmark cuts FY27 margin guidance to 21-22%, delays Envafolimab launch